USA – FDA issues platform technology designation draft guidance

The US Food and Drug Administration (FDA) has published a much-awaited draft guidance detailing how it plans to implement its new platform technology designation...

USA – Stakeholders provide feedback on FDA draft guidance on drug development for early...

Guidance for developing drugs to treat early Alzheimer’s disease should focus on factors such as cognitive changes and brain atrophy, according to comments submitted...

USA – FDA unveils draft guidance on REMS logic models

The US Food and Drug Administration (FDA) has released a draft guidance outlining the agency’s risk evaluation and mitigation strategy (REMS) logic model. FDA described...

USA – FDA exploring model master files to expedite generic drug development

The US Food and Drug Administration (FDA) is exploring the use of model master files (MMFs) to enable sponsors to use the same modeling...

USA – Emerging technologies and regulatory agency guidance for CGTs

Advances in cellular and gene therapies (CGTs) – referred to as advanced therapy medicinal products (ATMPs) in the EU – offer opportunities for treating...

USA – FDA drafts two guidances on safety testing for cell and gene therapy...

The US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) on Tuesday issued two draft guidances related to cell and...

USA – FDA issues three guidances to expand cancer clinical trial eligibility

The US Food and Drug Administration’s (FDA) has issued a trio of draft guidance documents that aim to promote greater participation and diversity in...
Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance

USA – FDA issues long-awaited LDT final rule

After years of jostling with industry, failed legislative efforts, and some false starts, the US Food and Drug Administration (FDA) has unveiled its plan...

USA – FDA updates guidance on promotional labeling and advertising of biosimilars

The US Food and Drug Administration (FDA) has published revised guidance on promotional labeling and advertising for prescription biosimilar drugs and their reference products. The...
Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2020

USA – CBER chief on remote work, CRISPR-Cas9, and rare disease gene therapy accelerated...

The use of CRISPR-Cas9 gene editing technology has potential to transform the field of gene therapy through its simple and cost-effective delivery mechanism, said...

NOS PROCHAINES FORMATIONS